Study of the antiarrhythmic activity of linear alkoxyphenylazalkanes in the model of reperfusion arrythmias in rats-Reference-Cited by-同舟云学术

Study of the antiarrhythmic activity of linear alkoxyphenylazalkanes in the model of reperfusion arrythmias in rats

Published:2023-07-19 Issue:2 Volume: Page:20-28
ISSN:2686-8830
Container-title:Pharmacokinetics and Pharmacodynamics
language:
Short-container-title:Fk&Fd

Author:

Barchukov V. V.¹^ORCID,Stolyaruk V. N.¹^ORCID,Tsorin I. B.¹^ORCID,Vititnova M. B.¹^ORCID,Kryzhanovskii S. А.¹^ORCID,Vorobieva T. Yu.¹^ORCID,Biryukova V. E.¹^ORCID,Mokrov G. V.¹^ORCID

Affiliation:

1. FSBI "Research Zakusov Institue of Pharmacology"

Abstract

The antiarrhythmic activity of bis-alkoxyphenyltriazaalkanes 1 and bis-alkoxyphenyldiazaalkanes 2 was analyzed in a model of reperfusion arrhythmia in rats. It was found that the key requirements for the compounds activity in this model are the use of 2,3,4 trimethoxyphenyl aromatic pharmacophores and the presence of a central nitrogen atom in the linker. The most active compounds were ALM-802 (trihydrochloride N1–(2,3,4-trimethoxybenzyl)-N2– {2-[(2,3,4-trimethoxybenzyl)amino]ethyl}-1,2-ethanediamine) and ALM-811 (N1-(2,3,4-trimethoxybenzyl)-N3-{3-[(2,3,4-trimethoxybenzyl)amino]ethyl}-1,3-propanediamine trihydrochloride), which significantly prevented the development of ventricular tachycardias and/or ventricular fibrillation.

Publisher

Publishing House OKI

Subject

Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science

Reference23 articles.

1. Mokrov G. V. Kardioprotektornye sredstva s biaromaticheskoi strukturoi. Chast' 1. Blokatory kal'tsievykh kanalov. Farmakokinetika i farmakodinamika. 2021;(4):3–17. [Mokrov GV. Sardioprotective agents with biaromatic structure. Part 1. Calcium channel blockers. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2021;(4):3–17. (In Russ).]. DOI: 10.37489/2587-7836-2021-4-3-17.

2. Mokrov G. V. Kardioprotektornye sredstva s biaromaticheskoi strukturoi. Chast' 2. Blokatory HCN-kanalov. Farmakokinetika i farmakodinamika. 2022;(2):03–10. [Mokrov GV. Sardioprotective agents with biaromatic structure. Part 2. HCN channel blockers. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2022;(2):03–10. (In Russ).]. DOI: 10.37489/2587-7836-2022-2-03-10.

3. Mokrov G. V. Kardioprotektornye sredstva s biaromaticheskoi strukturoi. Chast' 3. Blokatory natrievykh kanalov. Farmakokinetika i farmakodinamika. 2022;(3):3–9. [Mokrov GV. Sardioprotective agents with biaromatic structure. Part 3. Sodium channel blockers. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2022;(3):3–9. (In Russ).]. DOI: 10.37489/2587-7836-2022-3-3-9.

4. Mokrov G. V. Kardioprotektornye sredstva s biaromaticheskoi strukturoi. Chast' 4. Blokatory i modulyatory kalievykh hERG-kanalov. Farmakokinetika i farmakodinamika. 2022;(4):3–19. [Mokrov GV. Sardioprotective agents with biaromatic structure. Part 4. Potassium hERG channels blockers and modulators. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2022;(4):3–19. (In Russ).]. DOI: 10.37489/2587-7836-2022-4-3-19.

5. Mokrov GV. Kardioprotektornye sredstva s biaromaticheskoi strukturoi. Chast' 5. Blokatory kalievykh kanalov Kv1.5. Farmakokinetika i Farmakodinamika. 2023. (v pechati). [Mokrov GV. Sardioprotective agents with biaromatic structure. Part 5. Kv1.5 potassium channel blockers. Farmakokinetika i farmakodinamika = Pharmacokinetics and pharmacodynamics. 2023. (in press). (In Russ).].